bioRxiv / medRxiv
open access
CC BY 4.0
Siglec-15 is a glyco-immune checkpoint in prostate cancer regulating immune evasion and metastasis
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer#833591
- Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors#1088261
- INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors#1162717
- Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted#812914
- Perioperative dynamics of siglec-15 and soluble PD-L1 in ovarian cancer surgery: Influence of anaesthetic technique on immune regulation#414196
Record · ID 668726
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive